

HNE AREA Intensive Care

Approved For: JHH and CMN ICU's and JHH HDU

KETAMINE

Trade Name:

Presentation: 200mg ampoule

Indications:

- Ketamine is an intravenous anaesthetic agent, which produces excellent analgesia in subanaesthetic doses. Ketamine's analgesic action is thought to be related to its antagonism of NMDA glutamate receptors in the spinal cord.
- It will generally be used as a second line drug. Neuropathic pain, eg. Guillain Barre Syndrome, peripheral nerve injury, recent limb amputation
- Musculoskeletal trauma where pain is not adequately controlled with opiates, eg. Morphine >8mg/hr
- Other opiate unresponsive pain patients

Administration; Dilution: 2 X 200mg ampoules to 40mls with saline - 10mg/ml

Initiation: 20-30mg bolus; if required.

IV infusion: 0.1-0.15 mg/kg/hr, approx 10mg/hr

Dose

Precautions

Side Effects:

- Dysphoria/hallucinations - reduce dose, benzodiazepine effective
- Sympathetic activation : tachycardia & hypertension
- Increased cerebral blood flow and cerebral O₂ consumption, possible increase in ICP
- Pulmonary hypertension
- Bronchodilation (a useful side effect)

Contraindications:

- Recent Head injury
- Neurosurgical patients
- Severe hypertension
- Unstable angina/ recent AMI
- Psychiatric disorders
- Thyrotoxicosis/ Pheochromocytoma

Compatibilities:

Created: 01-Aug-98 by Dr M Rowley Reviewed: 01-Apr-08 by Dr M rowley Guideline to be reviewed before : 01-Nov-09
These guidelines are intended for and to be used only by experienced critical care staff under direct supervision of Hunter Health Area Intensive Care Specialists in designated Hunter Health Area Critical Care Areas. The Authors will not be responsible for inappropriate use of these guidelines